Floridienne (FLOB) H2 2024 earnings summary

Executive summary

• Achieved record results in 2024, with EBITDA up 109% to EUR 116.8 million and net result rising to EUR 30.9 million, driven by strong performance in Life Sciences and successful integration of BIOTROP.

• Life Sciences Division saw robust growth in sales and profitability, especially in greenhouse crops and biological solutions for agriculture.

• Food Division reported higher turnover and improved profitability, maintaining margins and securing supplies.

• Chemicals Division experienced a temporary fall in profitability due to external factors but continued major investments in battery recycling.

Financial highlights

• Consolidated turnover increased to EUR 697.4 million from EUR 549.3 million year-over-year.

• EBITDA rose to EUR 116.8 million from EUR 56.0 million year-over-year.

• Net result after tax reached EUR 30.9 million, up from EUR 8.6 million year-over-year.

• Equity capital stood at EUR 633.0 million, with net financial debt at EUR 209.5 million as of year-end 2024.

• Proposed gross dividend of EUR 3.00 per share for 2024.

Outlook and guidance

• Divisions expect continued growth and improved results in 2025, supported by recent investments and expanded capacities.

• Life Sciences anticipates sustainable growth from global reach and expanded product portfolio.

• Food Division to focus on margin maintenance amid price pressures and expand cold sauces production.

• Chemicals Division to commission new processing capacities in 2025, with positive outlook for Turkish subsidiary Kimflor.